home / stock / aqst / aqst news

AQST News and Press, Aquestive Therapeutics Inc. From 01/19/24

Stock Information
Company Name: Aquestive Therapeutics Inc.
Stock Symbol: AQST
Market: NASDAQ
Website: aquestive.com
Menu
AQST AQST Quote AQST Short AQST News AQST Articles AQST Message Board
Get AQST Alerts

News, Short Squeeze, Breakout and More Instantly...
AQST - Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1

2024-01-19 17:05:19 ET Summary Aquestive Therapeutics is nearing a key topline readout for its Anaphylm sublingual film, a potential groundbreaking oral epinephrine treatment for severe allergic reactions. If the data is positive, Anaphylm could be heading for a possible New Drug ...
AQST - Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm(TM) (epinephrine) Sublingual Film

Commences initial Phase 3 study with first orally delivered epinephrine prodrug candidate Reaffirms topline data anticipated in first quarter 2024 WARREN, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestiv...

AQST - Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm(TM) at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting

WARREN, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...

AQST - Aquestive Therapeutics, Inc. (AQST) Q3 2023 Earnings Call Transcript

2023-11-07 13:39:10 ET Aquestive Therapeutics, Inc. (AQST) Q3 2023 Earnings Conference Call November 07, 2023 08:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice Preside...
AQST - Aquestive Therapeutics GAAP EPS of -$0.03 beats by $0.09, revenue of $13M beats by $1.49M

2023-11-06 16:55:25 ET More on Aquestive Therapeutics ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both Aquestive Therapeutics Q3 2023 Earnings Preview For further details see: Aquestive Therapeutics GAAP EPS o...

AQST - Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Reiterates commencement of pivotal pharmacokinetic (PK) study for Anaphylm™ (epinephrine) Sublingual Film expected in fourth quarter 2023 with topline data targeted for first quarter 2024 Completes debt refinancing resulting in approximately $28 million of cash savings through June of ...

AQST - Expected US Company Earnings on Monday, November 6th, 2023

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
AQST - Expected earnings - Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc. (AQST) is expected to report $-0.11 for Q3 2023

AQST - Aquestive Therapeutics Completes $45 Million Debt Refinancing

WARREN, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced the refinancing of its existing ...

AQST - Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET

WARREN, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...
Previous 10 Next 10